Get started
Author

Karma Dacosta

Observed names: Dacosta, Karma, K DaCosta, K. DaCosta, KARMA DACOSTA, Karma DaCosta
ORCID: 0000-0002-9600-1889
Observed ORCID: 0000-0002-9600-1889
OpenAlex ID: A5029127660
T follicular helper–like cells contribute to skin fibrosis
2018 · Devon K. Taylor, Nanette Mittereder, et al. · Science Translational Medicine · 113
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis
2018 · Keith E. Steele, Tze Heng Tan, et al. · Journal for ImmunoTherapy of Cancer · 99
PDF
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
2018 · Song Cho, Francesca Zammarchi, et al. · Molecular Cancer Therapeutics · 50
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
2019 · Michael Surace, Karma DaCosta, et al. · Journal of Visualized Experiments · 44
Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice
2016 · Nanette Mittereder, Ellen Kuta, et al. · The Journal of Immunology · 26
CTLA-4 Immunohistochemistry and Quantitative Image Analysis for Profiling of Human Cancers
2019 · Charles Brown, Farzad Sekhavati, et al. · Journal of Histochemistry & Cytochemistry · 24
Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy
2022 · Maria Letizia Giardino Torchia, Ryan Gilbreth, et al. · Cytotherapy · 21
PDF
Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer
2018 · Emily E. Bosco, R. James Christie, et al. · Oncotarget · 16
PDF
Effects of ICOS+ T cell depletion via afucosylated monoclonal antibody MEDI-570 on pregnant cynomolgus monkeys and the developing offspring
2017 · Simone M. Nicholson, Gianluca Carlesso, et al. · Reproductive Toxicology · 15
Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC
2025 · J. Lesniak, M. Schick, et al. · npj Precision Oncology · 5
PDF
Eosinophils and Il-5 Receptor in Covid-19 Postmortem Lung Tissue
2021 · CHRISTOPHER MCCRAE, JENNIFER CANN, et al. · CHEST Journal · 2
PDF
Loss of immune tolerance is controlled by ICOS in Sle1 mice
2017 · Nanette Mittereder, Ellen Kuta, et al. · The Journal of Immunology · 2
Abstract 2492: Enhanced patient selection for anti-PD-L1 treatment in metastatic NSCLC with quantitative continuous scoring of PD-L1
2024 · Jan Martin Lesniak, Markus Schick, et al. · Cancer Research · 1
339 Quantitative assessment of CAR-T cell therapy targets using computational pathology
2022 · Nathalie Harder, Markus Schick, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Chronic CNS Pathology is Associated with Abnormal Collagen Deposition and Fibrotic-like Changes
2021 · Daphne Palacios Macapagal, Jennifer Cann, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
PDF
112 Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy
2020 · Letizia Giardino, Ryan Gilbreth, et al. · Journal for ImmunoTherapy of Cancer · 1
Abstract A004: MEDI3726 (ADCT-401), a novel antibody-drug conjugate targeting PSMA, has potent in vivo antitumor activity in prostate cancer patient-derived xenograft models
2018 · Song Cho, Francesca Zammarchi, et al. · Cancer Research · 1
Abstract 3736: Application of circulating tumor cells and circulating cell-free DNA to assess the pharmacodynamic response to chemotherapy in xenograft models
2010 · Haifeng Bao, Patricia Burke, et al. · Cancer Research · 1
2791P Advancing SCLC biomarker discovery: AI-driven MHC-I quantification and impact of MHC-I on the tumor microenvironment
2025 · C. Eisen, F. Pollastri, et al. · Annals of Oncology
Abstract 2023: Multiplex immunofluorescence profiling of the tumor microenvironment and CD73: Activity of neoadjuvant oleclumab in patients with non-small-cell lung cancer in NeoCOAST
2024 · Ina Bisha, Tze Heng Tan, et al. · Cancer Research
Supplementary Methods from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
2023 · Song Cho, Francesca Zammarchi, et al.
Supplementary Figures S1-S7 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
2023 · Song Cho, Francesca Zammarchi, et al.
Supplementary Tables S1 to S4 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
2023 · Song Cho, Francesca Zammarchi, et al.
PDF
Data from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
2023 · Song Cho, Francesca Zammarchi, et al.
Abstract 759: Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer
2018 · Emily E. Bosco, Ronald J. Christie, et al. · Cancer Research
Works count: 28
Citation count: 423
H-index: 9
I10-index: 9
Year
Topic
Type